photo: ajmc.com
Feb 7, 2026, 15:24
Abeer Alanazi: Asundexian Reduces Stroke and Mortality Without Increased Bleeding
Abeer Alanazi, American Board Certified Pharmacotherapy Specialist and member at European Stroke Organisation (ESO), shared a post on LinkedIn.
“OCEANIC-STROKE
- Patients with non-cardioembolic ischemic stroke or TIA
- Concomitant dual antiplatelet therapy (DAPT)
- Asundexian initiated within 72 hours of symptom onset
- 6,162 patients received asundexian; 6,165 received placebo
- Treatment duration: 3–31 months
- 30% of patients had NIHSS >4
Efficacy
- Significant reduction in acute ischemic stroke (AIS)
- Significant reduction in cardiovascular mortality
- Significant reduction in all-cause mortality
Treatment effects were consistent across the overall population and all prespecified subgroups throughout the treatment period.
Safety
- No increase in major bleeding
- No increase in non-major bleeding
- No increase in symptomatic intracranial hemorrhage (sICH)
- No increase in hemorrhagic stroke
- No increase in fatal bleeding”

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 10:08Abdul Mannan: When Normal Blood Counts Hide Iron Deficiency
-
Nov 16, 2026, 09:47Ankit Kumar: A Memorable Experience at Haematocon 2026
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease